CDEK
← All trials

NCT06989112

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Mar 27, 2025
Primary completion
Jan 19, 2029
Completion date
Feb 19, 2031
First posted
May 25, 2025
Last posted
Nov 10, 2025
Enrollment
600
Arms / groups
3 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.